Andere Sprachen Ultragenyx Pharmaceutical Inc.

Aktien

A1XCY0

US90400D1081

RARE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 20.05.2024			% 5 Tage	% 1. Jan.
41,53 ^USD	-0,81 %		+1,39 %	-13,15 %

14.05.	Korro Bio Q1 Nettoverlust schrumpft; Kemi Olugemo zum Chief Medical Officer ernannt	MT
14.05.	Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	16:12
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	17.05.
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	14.05.
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference	07.05.
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference	07.05.
Ultragenyx: Q1 Earnings Snapshot	02.05.
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q1 Revenue $108.8M	02.05.
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update	02.05.
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	02.05.
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta	01.05.
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease	30.04.
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)	30.04.
Ultragenyx Pharmaceutical Inc. Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta (OI)	30.04.
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update	25.04.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - April 19, 2024	22.04.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	19.04.
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	15.04.
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology 2024 Annual Meeting	15.04.
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	15.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ultragenyx Pharmaceutical Inc.

Aktien

A1XCY0

US90400D1081

RARE

Andere Sprachen

Filter